144 related articles for article (PubMed ID: 35157829)
1. Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial.
Fennell DA; King A; Mohammed S; Greystoke A; Anthony S; Poile C; Nusrat N; Scotland M; Bhundia V; Branson A; Brookes C; Darlison L; Dawson AG; Gaba A; Hutka M; Morgan B; Bajaj A; Richards C; Wells-Jordan P; Thomas A;
Lancet Oncol; 2022 Mar; 23(3):374-381. PubMed ID: 35157829
[TBL] [Abstract][Full Text] [Related]
2. Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial.
Fennell DA; King A; Mohammed S; Branson A; Brookes C; Darlison L; Dawson AG; Gaba A; Hutka M; Morgan B; Nicholson A; Richards C; Wells-Jordan P; Murphy GJ; Thomas A;
Lancet Respir Med; 2021 Jun; 9(6):593-600. PubMed ID: 33515503
[TBL] [Abstract][Full Text] [Related]
3. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
Tolaney SM; Wardley AM; Zambelli S; Hilton JF; Troso-Sandoval TA; Ricci F; Im SA; Kim SB; Johnston SR; Chan A; Goel S; Catron K; Chapman SC; Price GL; Yang Z; Gainford MC; André F
Lancet Oncol; 2020 Jun; 21(6):763-775. PubMed ID: 32353342
[TBL] [Abstract][Full Text] [Related]
4. Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study.
van Zandwijk N; Pavlakis N; Kao SC; Linton A; Boyer MJ; Clarke S; Huynh Y; Chrzanowska A; Fulham MJ; Bailey DL; Cooper WA; Kritharides L; Ridley L; Pattison ST; MacDiarmid J; Brahmbhatt H; Reid G
Lancet Oncol; 2017 Oct; 18(10):1386-1396. PubMed ID: 28870611
[TBL] [Abstract][Full Text] [Related]
5. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
Nowak AK; Lesterhuis WJ; Kok PS; Brown C; Hughes BG; Karikios DJ; John T; Kao SC; Leslie C; Cook AM; Pavlakis N; Briscoe K; O'Byrne KJ; Karapetis CS; Lam WS; Langford A; Yip S; Stockler MR
Lancet Oncol; 2020 Sep; 21(9):1213-1223. PubMed ID: 32888453
[TBL] [Abstract][Full Text] [Related]
6. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial.
Ceresoli GL; Aerts JG; Dziadziuszko R; Ramlau R; Cedres S; van Meerbeeck JP; Mencoboni M; Planchard D; Chella A; Crinò L; Krzakowski M; Rüssel J; Maconi A; Gianoncelli L; Grosso F
Lancet Oncol; 2019 Dec; 20(12):1702-1709. PubMed ID: 31628016
[TBL] [Abstract][Full Text] [Related]
7. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.
Maio M; Scherpereel A; Calabrò L; Aerts J; Perez SC; Bearz A; Nackaerts K; Fennell DA; Kowalski D; Tsao AS; Taylor P; Grosso F; Antonia SJ; Nowak AK; Taboada M; Puglisi M; Stockman PK; Kindler HL
Lancet Oncol; 2017 Sep; 18(9):1261-1273. PubMed ID: 28729154
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
Scherpereel A; Mazieres J; Greillier L; Lantuejoul S; Dô P; Bylicki O; Monnet I; Corre R; Audigier-Valette C; Locatelli-Sanchez M; Molinier O; Guisier F; Urban T; Ligeza-Poisson C; Planchard D; Amour E; Morin F; Moro-Sibilot D; Zalcman G;
Lancet Oncol; 2019 Feb; 20(2):239-253. PubMed ID: 30660609
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.
Calabrò L; Morra A; Fonsatti E; Cutaia O; Fazio C; Annesi D; Lenoci M; Amato G; Danielli R; Altomonte M; Giannarelli D; Di Giacomo AM; Maio M
Lancet Respir Med; 2015 Apr; 3(4):301-9. PubMed ID: 25819643
[TBL] [Abstract][Full Text] [Related]
10. EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study.
Zauderer MG; Szlosarek PW; Le Moulec S; Popat S; Taylor P; Planchard D; Scherpereel A; Koczywas M; Forster M; Cameron RB; Peikert T; Argon EK; Michaud NR; Szanto A; Yang J; Chen Y; Kansra V; Agarwal S; Fennell DA
Lancet Oncol; 2022 Jun; 23(6):758-767. PubMed ID: 35588752
[TBL] [Abstract][Full Text] [Related]
11. NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial.
Gregorc V; Gaafar RM; Favaretto A; Grossi F; Jassem J; Polychronis A; Bidoli P; Tiseo M; Shah R; Taylor P; Novello S; Muzio A; Bearz A; Greillier L; Fontana F; Salini G; Lambiase A; O'Brien M
Lancet Oncol; 2018 Jun; 19(6):799-811. PubMed ID: 29753703
[TBL] [Abstract][Full Text] [Related]
12. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial.
Disselhorst MJ; Quispel-Janssen J; Lalezari F; Monkhorst K; de Vries JF; van der Noort V; Harms E; Burgers S; Baas P
Lancet Respir Med; 2019 Mar; 7(3):260-270. PubMed ID: 30660511
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study.
Douma LH; Lalezari F; van der Noort V; de Vries JF; Monkhorst K; Smesseim I; Baas P; Schilder B; Vermeulen M; Burgers JA; de Gooijer CJ
Lancet Oncol; 2023 Nov; 24(11):1219-1228. PubMed ID: 37844598
[TBL] [Abstract][Full Text] [Related]
14. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
Calabrò L; Morra A; Fonsatti E; Cutaia O; Amato G; Giannarelli D; Di Giacomo AM; Danielli R; Altomonte M; Mutti L; Maio M
Lancet Oncol; 2013 Oct; 14(11):1104-1111. PubMed ID: 24035405
[TBL] [Abstract][Full Text] [Related]
15. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.
Alley EW; Lopez J; Santoro A; Morosky A; Saraf S; Piperdi B; van Brummelen E
Lancet Oncol; 2017 May; 18(5):623-630. PubMed ID: 28291584
[TBL] [Abstract][Full Text] [Related]
16. Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial.
Scagliotti GV; Gaafar R; Nowak AK; Nakano T; van Meerbeeck J; Popat S; Vogelzang NJ; Grosso F; Aboelhassan R; Jakopovic M; Ceresoli GL; Taylor P; Orlandi F; Fennell DA; Novello S; Scherpereel A; Kuribayashi K; Cedres S; Sørensen JB; Pavlakis N; Reck M; Velema D; von Wangenheim U; Kim M; Barrueco J; Tsao AS
Lancet Respir Med; 2019 Jul; 7(7):569-580. PubMed ID: 31103412
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial.
Chu Q; Perrone F; Greillier L; Tu W; Piccirillo MC; Grosso F; Lo Russo G; Florescu M; Mencoboni M; Morabito A; Cecere FL; Ceresoli GL; Dawe DE; Zucali PA; Pagano M; Goffin JR; Sanchez ML; Gridelli C; Zalcman G; Quantin X; Westeel V; Gargiulo P; Delfanti S; Tu D; Lee CW; Leighl N; Sederias J; Brown-Walker P; Luo Y; Lantuejoul S; Tsao MS; Scherpereel A; Bradbury P; Laurie SA; Seymour L
Lancet; 2023 Dec; 402(10419):2295-2306. PubMed ID: 37931632
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G; Mazieres J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Rivière F; Janicot H; Gervais R; Locher C; Milleron B; Tran Q; Lebitasy MP; Morin F; Creveuil C; Parienti JJ; Scherpereel A;
Lancet; 2016 Apr; 387(10026):1405-1414. PubMed ID: 26719230
[TBL] [Abstract][Full Text] [Related]
19. Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.
Buikhuisen WA; Burgers JA; Vincent AD; Korse CM; van Klaveren RJ; Schramel FM; Pavlakis N; Nowak AK; Custers FL; Schouwink JH; Gans SJ; Groen HJ; Strankinga WF; Baas P
Lancet Oncol; 2013 May; 14(6):543-51. PubMed ID: 23583604
[TBL] [Abstract][Full Text] [Related]
20. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.
Bahadoer RR; Dijkstra EA; van Etten B; Marijnen CAM; Putter H; Kranenbarg EM; Roodvoets AGH; Nagtegaal ID; Beets-Tan RGH; Blomqvist LK; Fokstuen T; Ten Tije AJ; Capdevila J; Hendriks MP; Edhemovic I; Cervantes A; Nilsson PJ; Glimelius B; van de Velde CJH; Hospers GAP;
Lancet Oncol; 2021 Jan; 22(1):29-42. PubMed ID: 33301740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
